

## Bipartisan majorities believe NAFTA 2.0 should not trade away Americans' access to more affordable medicine.

**Americans are clear:** a renegotiated NAFTA should not limit access to generics and biosimilars.

**There is strong support among Americans that NAFTA 2.0 should decrease prescription drug costs by enhancing generic and biosimilar competition.**



**2 in 3**

Americans believe trade policy should increase generic and biosimilar drug competition in the U.S. pharmaceutical industry.



**4 in 5**

Americans believe trade policy should seek to lower drug prices for U.S. patients.



**4 in 5**

Americans believe NAFTA 2.0 should decrease prescription drug prices by enhancing competition.

**Most Americans believe** NAFTA 2.0 should significantly reduce the time period of exclusivity for biologic drugs.

**Americans across party lines believe that NAFTA 2.0 should have Intellectual Property (IP) provisions that balance competition and innovation.**



**2 in 3**

Americans believe NAFTA 2.0 should include provisions that improve access to biosimilar medicines for patients in the U.S.

Generic medicines saved America \$265 billion last year alone. Biologics - which currently lack robust competition through biosimilars - make up the majority of drug spending and drug price increases in the U.S.

**Americans are clear that trade policy should not trade away patient access to affordable generic and biosimilar medicines.**

**CLICK HERE NOW**

to contact lawmakers to protect the savings all patients receive from FDA approved generic and biosimilar medicines. Encourage Congress not to give brand name pharmaceutical companies larger monopolies in trade agreements. This only drives up costs for all prescription drugs.

### METHODOLOGY

This poll was conducted from September 14-17, 2018, among a national sample of 2203 Adults. The interviews were conducted online and the data were weighted to approximate a target sample of Adults based on age, race/ethnicity, gender, educational attainment, and region. Results from the full survey have a margin of error of plus or minus 2 percentage points.